Clinical Trial Update: The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Adolescents With Impulsivity and Aggressive Behavior in Conduct Disorder This Study is Not Being Conducted in the United States. [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating oral oxcarbazepine (300–1200 mg/day) as adjuvant therapy for adolescents with impulsivity and aggressive behavior in conduct d…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Conduct Disorder

Drugs mentioned

• Oxcarbazepine (Oxcarbazepine)

Snippet

Sponsor: Novartis | Conditions: Conduct Disorder | Phase 4 | Status: COMPLETED